Common GLP-1 Weight-loss Side Effects
US$ 26.65
glp 1 and sarcopenia Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? GLP‐1 receptor agonists and muscle
Description
Based on positive clinical trial results, Novo Nordisk recently received approval from the FDA to add a new indication to Victoza: lowering cardiovascular risks in type 2 diabetes patients with established cardiovascular disease [178]
Weight change and risk of venous thromboembolism: the Troms study
However, certain metabolic and clinical patterns may suggest suboptimal GLP-1 activity, though these signs are non-specific and can result from numerous other conditions
The medication works by reducing appetite and increasing satiety, which leads to a lower calorie intake and an initial rapid weight loss
PureWay Blog
They may face new restrictions
